同和药业(300636) - 2017 Q1 - 季度财报

Financial Performance - Total revenue for Q1 2017 was CNY 65,210,354.97, an increase of 12.63% compared to CNY 57,897,096.69 in the same period last year[8] - Net profit attributable to shareholders decreased by 10.63% to CNY 13,379,087.27 from CNY 14,969,666.95 year-on-year[8] - Basic earnings per share decreased by 12.00% to CNY 0.22 from CNY 0.25 in the same period last year[8] - The net profit for the reporting period was 13.38 million RMB, a decrease of 10.63% year-over-year[22] - The total profit for Q1 2017 was CNY 15,781,207.35, down from CNY 17,646,910.44 in the same period last year, representing a decline of approximately 10.0%[44] - The company's operating profit for Q1 2017 was CNY 15,368,532.33, a decrease of about 5.0% from CNY 17,239,106.20 in the previous year[44] Cash Flow - Net cash flow from operating activities was negative CNY 7,847,273.36, a decline of 130.16% compared to CNY 26,018,047.36 in the previous year[8] - Cash inflow from operating activities totaled CNY 59,332,839.71, a decrease from CNY 78,170,268.41 in the previous period[51] - The total cash outflow for operating activities was 65,078,339.16 CNY, compared to 50,902,580.07 CNY previously[54] - The net cash flow from financing activities was 265,039,437.03 CNY, compared to only 1,577,256.81 CNY previously[53] - The company reported a total cash outflow from investing activities of 13,632,723.02 CNY, compared to 6,398,846.25 CNY in the prior period[52] Assets and Liabilities - Total assets increased by 68.20% to CNY 704,708,844.31 from CNY 418,960,553.45 at the end of the previous year[8] - The total liabilities increased to CNY 118,474,677.70 from CNY 114,305,474.11, a rise of 3.8%[37] - The equity attributable to shareholders of the parent company reached CNY 586,234,166.61, up from CNY 304,655,079.34, indicating an increase of 92.5%[38] Operational Highlights - The company has completed its operational plan for Q1 2017, achieving expected targets[23] - There were no changes in the top five suppliers or customers during the reporting period[23] - The company has not encountered any significant risks or difficulties that would adversely affect future operations[23] Government and Compliance - The company reported government subsidies of CNY 436,675.02, contributing to non-recurring gains[9] - The company emphasizes safety and environmental protection, implementing a comprehensive management system to ensure compliance with regulations[12] Inventory and Receivables - Accounts receivable rose by 107.21% compared to the beginning of the period, attributed to business expansion and extended payment terms for some customers[20] - The company's inventory increased to CNY 142,307,298.67 from CNY 128,406,007.64, a rise of 10.8%[39] Shareholder and Financing Activities - The company did not engage in any repurchase transactions among the top 10 shareholders during the reporting period[17] - The total amount of raised funds is CNY 26,303,000, with no funds utilized in the current quarter[27] - The company received 268,200,000.00 CNY from investment absorption, with no previous amount reported[56]